- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The FDA approved Insmed's BRINSUPRI therapy on August 26, 2025, noting market comparisons between the US and EU4 markets.
4 reports, 3 independent
Updated Aug 26
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA approved Insmed's BRINSUPRI therapy on August 26, 2025, noting market comparisons between the US and EU4 markets.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approved Insmed's BRINSUPRI therapy, noting market comparisons between the US and EU4 markets.1 source
Insmed partners for the launch of Brinsupri.1 source
Insmed selected PANTHERx Rare in Pittsburgh to dispense BRINSUPRI.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- The FDA operates under US law to evaluate international clinical data.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- A product was launched in the U.S. market following FDA involvement.
- A 2019 finding indicated that the US regulatory process was slower than European standards.
- FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.
Coverage
Newest first; wire copies grouped- GlobeNewswireNon-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight Insmed’s BRINSUPRI (brensocatib) has reached a significant regulatory milestone, ear
- PR NewswireVytlOne Announces New Partnership with Insmed AMARILLO, Texas, Aug. 13, 2025 /PRNewswire/ -- Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider
- PR NewswirePANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis PITTSBURGH, Aug. 13, 2025 /PRNewswire/ -- PANTHERx® Rare Pharmacy, a lea
- Insider MonkeyInsmed’s Pipeline Growth With Brensocatib Approval And Phase 3 Trials Insmed Incorporated (NASDAQ:INSM) is one of the 10 Stocks with Huge Catalysts on the Horizon. The company eyes Brensocatib approv